| Cellares–8VC: investment, 202105 financing round Series B totalling $82m incl existing + co-investor 8VC |
2021-05-05 |
| Cellares–Decheng Capital: investment, 202105 financing round Series B totalling $82m incl new + lead investor Decheng Capital |
2021-05-05 |
| Cellares–Eclipse Ventures: investment, 202105 financing round Series B totalling $82m incl existing + co-lead investor Eclipse Ventures |
2021-05-05 |
| Cellares–SEVERAL: investment, 202105 financing round Series B $82m led by Decheng Capital + Eclipse Ventures |
2021-05-05 |
| Cellares–Skyviews Life Science: investment, 202105 financing round Series B totalling $82m incl new + co-investor Skyviews Life Science |
2021-05-05 |
| Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial |
2021-05-05 |
| Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
| Athenex–Cooley: legal services, 202105 supply service Cooley (UK) acted as sole advisor to Athenex with regard to acquisition of Kuur Therapeutics |
2021-05-04 |
| Kuur Therapeutics–Athenex: investment, 202105 acquisition $70m upfront (mainly in shares) + $115m milestones by Athenex |
2021-05-04 |
| Kuur Therapeutics–HMB Legal Counsel: legal services, 202105 supply service HMB Legal legal advisor to Kuur with regard to acquisition by Athenex |
2021-05-04 |
| Kuur Therapeutics–SVB: financial services, 202105 supply service SVB Lerrink financial adivsor to Kuur with regard to acquisition by Athenex |
2021-05-04 |
| Oxford Nanopore–SEVERAL: investment, 202105 financing round £195m from new + existing investors |
2021-05-04 |
| Aquila Biolabs–Scientific Industries: investment, 202104 acquisition of Aquila Biolabs GmbH by Scientific Bioprocessing Inc |
2021-04-30 |
| Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management |
2021-04-29 |
| Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital |
2021-04-29 |
| Forge Biologics–SEVERAL: investment, 202104 financing round Series B $120m led by RA Capital |
2021-04-29 |
| Valneva–SEVERAL: investment, 202104– European private placement ANNOUNCED |
2021-04-29 |
| Valneva–SEVERAL: investment, 202104– US IPO of ADSs at Nasdaq Global Market ANNOUNCED |
2021-04-29 |
| Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe |
2021-04-28 |
| Kaia Health–3VC: investment, 202104 financing round Series C totalling $75m incl existing + co-investor 3VC |
2021-04-28 |
| Kaia Health–A Round Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor A Round Capital |
2021-04-28 |
| Kaia Health–Balderton Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Balderton Capital |
2021-04-28 |
| Kaia Health–Eurazeo: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Eurazeo |
2021-04-28 |
| Kaia Health–Heartcore Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Heartcore Capital |
2021-04-28 |
| Kaia Health–Hot Cherry PR: public relations, 202104 service existent by Hot Cherry PR |
2021-04-28 |
| Kaia Health–OTHER: investment, 202104 financing round Series C totalling $75m incl undisclosed growth equity fund as lead investor |
2021-04-28 |
| Kaia Health–SEVERAL: investment, 202104 financing round Series C $75m led by undisclosed growth equity fund |
2021-04-28 |
| Kaia Health–Symphony Ventures: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Symphony Ventures |
2021-04-28 |
| Kaia Health–UnitedHealth: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Optum Ventures |
2021-04-28 |
| Exscientia–BlackRock: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BlackRock |
2021-04-27 |
| Exscientia–BMS: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BMS |
2021-04-27 |
| Exscientia–Casdin Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Casdin Capital |
2021-04-27 |
| Exscientia–Farallon Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Farallon Capital |
2021-04-27 |
| Exscientia–GT Healthcare Capital Partners: investment, 202104 financing round Series D totalling $225m incl co-investor GT Healthcare |
2021-04-27 |
| Exscientia–Hongkou: investment, 202104 financing round Series D totalling $225m incl co-investor Hongkou |
2021-04-27 |
| Exscientia–Laurion Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Laurion Capital |
2021-04-27 |
| Exscientia–Marshall Wace: investment, 202104 financing round Series D totalling $225m incl co-investor Marshall Wace |
2021-04-27 |
| Exscientia–Nan Fung: investment, 202104 financing round Series D totalling $225m incl co-investor Pivotal bioVenture Partners |
2021-04-27 |
| Exscientia–Novo Group: investment, 202104 financing round Series D totalling $225m incl existing + co-investor Novo Holdings |
2021-04-27 |
| Exscientia–SEVERAL: investment, 202104 financing round Series D $225m led by SoftBank Vision Fund 2 |
2021-04-27 |
| Exscientia–SoftBank: investment, 202104 financing round Series D totalling $225m incl lead investor SoftBank Vision Fund 2 |
2021-04-27 |
| Exscientia–SoftBank: investment, 202104– equity commitment up to $300m by SoftBank than can be drawn at Exscientia’s discretion |
2021-04-27 |
| Exscientia–United Arab Emirates (govt): investment, 202104 financing round Series D totalling $225m incl co-investor Mubadala Investment Company |
2021-04-27 |
| Molecular Partners–SEVERAL: investment, 202104– US IPO at Nasdaq FILED |
2021-04-23 |
| Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall |
2021-04-22 |
| Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I |
2021-04-20 |
| Forbion–Wealth Management Partners: investment, 202104 final closing at €360m of Forbion Growth Opportunities Fund I incl investor WMP |
2021-04-20 |
| Mestag Therapeutics–JnJ: investment, 202104 seed financing round totalling $11m incl Johnson & Johnson Innovation JJDC Inc |
2021-04-20 |
| Mestag Therapeutics–SEVERAL: investment, 202104 seed financing round $11m with SV Health Investors + JJDC |
2021-04-20 |
| Sense Biodetection–Koch Industries: investment, 202104 financing round Series B totalling $50m incl new + lead investor Koch Disruptive Technologies |
2021-04-20 |
| Sense Biodetection–SEVERAL: investment, 202104 financing round Series B $50m led by Koch Disruptive Technologies |
2021-04-20 |
| Lumicks–Farallon Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Farallon Capital |
2021-04-16 |
| Lumicks–Irving Investors: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Irving Investors |
2021-04-16 |
| Lumicks–Lauxera Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Lauxera Capital |
2021-04-16 |
| Lumicks–Parian Global Management: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Parian Global Mgt |
2021-04-16 |
| Lumicks–Pura Vida Investments: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Pura Vida |
2021-04-16 |
| Lumicks–SEVERAL: investment, 202104 financing round Series D $93m preferred shares led by Farallon Capital + Lauxera Capital |
2021-04-16 |
| Lumicks–Softbank: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Softbank Vision 2 |
2021-04-16 |
| Lumicks–T Rowe Price: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor funds managed by T Rowe Price |
2021-04-16 |
| Alchemab–RA Capital: investment, 202104 financing round Series B totalling £60m incl lead investor RA Capital Management |
2021-04-15 |
| Alchemab–SEVERAL: investment, 202104 financing round Series B £60m led by RA Capital Management |
2021-04-15 |
| Alligator Bioscience–MacroGenics: antibody cancer drug, 202104– collab research using Neo-X-Prime plus DART+TRIDENT technologies against two targets |
2021-04-15 |
| ATMPS–Oribiotech: CAGT manufacturing technology, 202104– collab ww for integrated digital patform for CAGT developers using Hataali platform |
2021-04-14 |
| Jaguar Gene Therapy–SEVERAL: investment, 202104 financing round Series B $139m co-led by Eli Lilly + Deerfield Management |
2021-04-13 |
| Quercis Pharma–Rx Communications: public relations, 202104 service existent IR by Rx Communications Group |
2021-04-13 |
| Repertoire Immune Medicines–SEVERAL: investment, 202104 financing round Series B $189m incl Flagship Pioneering + Softbank + PSP Investments et al |
2021-04-13 |
| Siemens–Biognosys: MS-based biomarker discovery, 202104– strategic agreem marker discovery using HRM-MS for Dx assay development with S Healthineers |
2021-04-13 |
| Luminex–DiaSorin: investment, 202104– acquisition $1.8b in cash for $37/share by DiaSorin ANNOUNCED |
2021-04-11 |
| Tidal Therapeutics–Sanofi: investment, 202104 acquisition $160m upfront + $310m milestones by Sanofi |
2021-04-09 |
| Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED |
2021-04-08 |
| Metagenomi–RA Capital: investment, 202104 financing round Series A extension totalling $10m incl new investor RA Capital Management |
2021-04-07 |
| Metagenomi–SEVERAL: investment, 202104 financing round Series A extension $10m with RA Capital Management closing total Series A at $75m |
2021-04-07 |
| OncoResponse–Helsinn: investment, 202103 financing round Series C totalling $40.6m incl existing + co-investor 3B Future Health Fund |
2021-03-31 |
| OncoResponse–SEVERAL: investment, 202103 financing round Series C $40.6m led by Magnetar Group |
2021-03-31 |
| Pyxis Oncology–LifeSci: public relations, 202103 supply service existent by LifeSci Communications |
2021-03-30 |
| Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience |
2021-03-30 |
| Gyroscope Therapeutics–Cambridge Innovation Capital: investment, 202103 financing round Series C totalling $148m incl co-investor CIC |
2021-03-26 |
| Gyroscope Therapeutics–Fosun: investment, 202103 financing round Series C totalling $148m incl co-investor Fosun Pharma |
2021-03-26 |
| Gyroscope Therapeutics–OTHER: investment, 202103 financing round Series C totalling $148m incl co-investor undisclosed healthcare focused fund |
2021-03-26 |
| Gyroscope Therapeutics–SEVERAL: investment, 202103 financing round Series C $148m led by Forbion Growth I |
2021-03-26 |
| Gyroscope Therapeutics–Sofinnova: investment, 202103 financing round Series C totalling $148m incl co-investor Sofinnova Investments |
2021-03-26 |
| Gyroscope Therapeutics–Syncona: investment, 202103 financing round Series C totalling $148m incl existing + co-investor Syncona |
2021-03-26 |
| Gyroscope Therapeutics–T Rowe Price: investment, 202103 financing round Series C totalling $148m incl co-investor T Rowe Price Associates Inc |
2021-03-26 |
| Gyroscope Therapeutics–Tetragon Financial Group: investment, 202103 financing round Series C totalling $148m incl co-investor TFG |
2021-03-26 |
| Dropprint Genomics––Immunai: investment, 202103 acquisition of Dropprint Genomics by Immunai |
2021-03-25 |
| Leyden Laboratories–Alphabet: investment, 202103 financing round Series A totalling €40m incl lead investor GV |
2021-03-25 |
| Leyden Laboratories–Brook Byers: investment, 202103 financing round Series A totalling €40m incl co-investor Brook Byers |
2021-03-25 |
| Leyden Laboratories–Casdin Capital: investment, 202103 financing round Series A totalling €40m incl co-investor Casdin Capital |
2021-03-25 |
| Leyden Laboratories–F-Prime: investment, 202103 financing round Series A totalling €40m incl co-investor F-Prime |
2021-03-25 |
| Leyden Laboratories–LifeSci: public relations, 202103 supply service existent by LifeSci Communications |
2021-03-25 |
| Leyden Laboratories–SEVERAL: investment, 202103 financing round Series A €40m led by GV |
2021-03-25 |
| Scipher Medicine–Alumni Ventures: investment, 202103 financing round Series C totalling $82m incl exisiting + co-investor Alumni Ventures |
2021-03-24 |
| Scipher Medicine–aMoon: investment, 202103 financing round Series C totalling $82m incl co-lead investor aMoon |
2021-03-24 |
| Scipher Medicine–Echo Health Ventures: investment, 202103 financing round Series C totalling $82m incl co-investor Echo Health Ventures |
2021-03-24 |
| Scipher Medicine–Khosla Ventures: investment, 202103 financing round Series C totalling $82m incl exisiting + co-investor Khosla Ventures |
2021-03-24 |
| Scipher Medicine–Northpond Ventures: investment, 202103 financing round Series C totalling $82m incl co-lead investor Northpond Ventures |
2021-03-24 |
| Scipher Medicine–SEVERAL: investment, 202103 financing round Series C $82m co-led by aMoon + Northpond Ventures |
2021-03-24 |
| 1910 Genetics–SEVERAL: investment, 202103 financing round Series A $22m co-led by M12 + Playground Global |
2021-03-23 |
| Dunad Therapeutics–Epidarex Capital: investment, 2020–202103 Dunad emerges from stealh with seed financing from Epidarex Capital |
2021-03-23 |
| Dunad Therapeutics–Huntsworth: public relations, 202103 service existent by Citigate Dewe Rogerson |
2021-03-23 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
